Leading-edge technologies in the fight against cancer
We are a next generation radiopharmaceutical company, taking cancer head on.
Thank you! Your submission has been received!
POINT Biopharma to Participate in Upcoming Investor Conferences
POINT will participate in the following summer investor conferences:
POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial
Mr. Horvath will lead the commercialization of POINT’s pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer Radioligand Therapy Franchise at Advanced Accelerator Applications (a Novartis Company).